Vitiligo
Conditions
Keywords
Vitiligo, Laser, Segmental vitiligo, Acral vitiligo
Brief summary
The purpose of this study is the evaluate the efficacy of using a low-energy 635 nm visible light laser in the treatment of various recalcitrant forms of vitiligo.
Detailed description
Vitiligo is a pigmentary disorder characterized by depigmented and hypopigmented macules and patches. There are forms of vitiligo which are more resistant to treatment, including segmental vitiligo and acral vitiligo. Previous studies have shown that a low energy helium-neon (633 nm) laser can cause increased proliferation of melanocytes and repigmentation in segmental-type vitiligo. The goal of this study is to verify these results and show efficacy in other recalcitrant forms of vitiligo including acral vitiligo and post melanocyte-keratinocyte transplantation vitiligo.
Interventions
PROCEDURELaser treatment
Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
Sponsors
Henry Ford Health System
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Be at least 18 years old * Have active or stable segmental vitiligo on the neck or face, acral vitiligo, or have undergone recent melanocyte-keratinocyte transplantation procedure (MKTP) * Agree to abide by the Investigator's guidelines regarding photosensitizing drugs and photoprotection * Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form * Agree to follow and undergo all study-related procedures
Exclusion criteria
* Women who are lactating, pregnant, or planning to become pregnant * Patients with a recent history of melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation * Patients with a known history of photosensitivity disorders * Photosensitizing medications may be continued throughout of the study at the discretion of the investigator * Patients with a known history of melanoma or non-melanoma skin cancers * Concomitant use of tanning beds * Any reason the investigator feels the patient should not participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent repigmentation | 24 clinic visits over 12 weeks |
Outcome results
None listed